GSK Drops Out Of Auction For Pfizer's Consumer Health Unit

The acquisition of Pfizer's consumer health business, which includes big named products such as Advil painkillers and Centrum multivitamins, has proven too big and too costly for GSK investors to stomach.

Dalmatians
GSK has turned tail on the idea of bidding for Pfizer's consumer health unit

GlaxoSmithKline PLC has bowed out of the auction for Pfizer Inc.'s consumer health business – it’s a good move by the UK giant, which recently laid out a strategy that focused on growth in pharmaceuticals.

While a mammoth acquisition in the over-the-counter sector would fit GSK's modus operandi, consumer health units are struggling in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.